AI Article Synopsis
- Researchers aimed to improve endoscopic detection of Barrett's esophagus using molecular endoscopic imaging (MEI) with nanoparticles (NPs) and fluorescently labeled antibodies, addressing challenges in identifying premalignant lesions.
- Seven patients with Barrett's esophagus provided biopsy samples that were treated with NPs and examined for fluorescence intensity, focusing on the presence of goblet cells indicative of metaplasia.
- The study found that MEI with NPs produced significantly stronger fluorescence signals than traditional methods, successfully correlating with histopathological results for identifying Barrett's metaplasia.
Article Abstract
Background And Study Aims: Despite major technical advancements, endoscopic surveillance for detecting premalignant lesions in Barrett's esophagus is challenging because of their flat appearance with only subtle morphological changes. Molecular endoscopic imaging (MEI) using nanoparticles (NPs), coupled with fluorescently labeled antibody permits visualization of disease-specific molecular alterations. The aim of this ex vivo study was to assess the diagnostic applicability of MEI with NPs to detect Barrett's metaplasia.
Patients And Methods: Seven patients undergoing endoscopic surveillance of known Barrett's esophagus were recruited. Freshly resected biopsy specimens were incubated with NPs coupled with FITC labeled Muc-2 antibodies and examined with MEI. Fluorescence intensity from Barrett's mucosa and control specimens were compared, followed by histological confirmation.
Results: Fluorescence signals, indicating the presence of goblet cells, were noted for traditional MEI using Muc-2 antibodies in Barrett's intestinal metaplasia. Significantly stronger fluorescence signals were achieved with NPs coupled with FITC-conjugated Muc-2 antibodies. The results of MEI with NPs for the prediction of Barrett's metaplasia correlated with the final histopathological examination in all the cases.
Conclusions: Highly-specific NPs detected Barrett's metaplasia more efficiently than conventional MEI in this first feasibility study. MEI was as effective as standard histopathology for identifying Muc-2 containing goblet cells for diagnosis of Barrett's metaplasia. (DRKS-ID: DRKS00017747).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529275 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239814 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- Endoscopic ablation is the primary treatment for dysplastic Barrett's esophagus (BE), primarily utilizing radiofrequency ablation (RFA) and argon plasma coagulation (APC) in Polish medical centers.
- A retrospective analysis of 160 adult patients revealed high rates of complete remission for intestinal metaplasia (80.0%) and dysplasia (93.8%), alongside a manageable adverse event rate, with 30.6% reporting minor and 5.6% major complications.
- The study also identified that RFA, used more for severe cases, had a higher failure rate compared to APC/h-APC, particularly in patients with long-segment BE and diabetes, suggesting specific risk factors for less favorable treatment outcomes
Prevalence of Abnormalities at Tandem Endoscopy in Patients Referred for Colorectal Cancer Screening/Surveillance Colonoscopy.
Cancers (Basel)
November 2024
Department of Gastroenterology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Performing a tandem endoscopy and colonoscopy in selected individuals has advantages, such as the early detection of benign and/or precancerous foregut diseases; it is efficient, and it may allow added therapies. It may also have disadvantages, such as generating anxiety from false-positive screening, possible harm from further testing, and unproven cost-effectiveness. We aimed to examine the prevalence of foregut endoscopic and histologic abnormalities in subjects referred for screening/surveillance colonoscopy who also underwent a tandem endoscopy.
View Article and Find Full Text PDFProgression to cancer in patients with confirmed dysplasia compared to dysplasia downgraded to non-dysplastic metaplasia in Barrett's esophagus: a retrospective cohort study in Sweden.
Clin Endosc
November 2024
Department of Upper Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden.
Article Synopsis
- The study investigated the progression risk of non-dysplastic Barrett's esophagus (NDBE) compared to low-grade dysplasia (LGD) and indefinite for dysplasia (IND) among patients reviewed by expert pathologists.
- Out of 423 patients with dysplasia, a significant percentage were reclassified, with 8% eventually developing cancer during follow-up, particularly within the first five years.
- The findings indicate that the long-term cancer risk is similar for patients with confirmed LGD and IND, suggesting they should have comparable management strategies.
Clinical application of capsule sponge testing in symptomatic reflux disease: a national prospective cohort study.
BMC Gastroenterol
November 2024
Centre for Sustainable Delivery, Golden Jubilee National Hospital, Clydebank, Glasgow, G81 4DN, UK.
Background: Capsule sponge testing, using an oesophageal cell collection device with biomarkers, was implemented nationally across Scotland in 2020 for symptomatic reflux patients referred to secondary care for non-urgent endoscopy. The aim was to use capsule sponge testing as a triage tool to reduce pressures on the endoscopy service during COVID-19, focus endoscopy resources on those most likely to have pathology and streamline the patient pathway. This prospective cohort study presents the first real-world results and evaluates the clinical application of capsule sponge testing in symptomatic reflux disease based on endoscopic biopsy results.
View Article and Find Full Text PDFADENOCARCINOMA AND DYSPLASIA IN BARRETT ESOPHAGUS: CRITICAL ANALYSIS OF RISK FACTORS AND SURVEILLANCE PROTOCOLS.
Arq Bras Cir Dig
November 2024
Universidade de São Paulo, Faculty of Medicine, Department of Gastroenterology - São Paulo (SP), Brazil.
Background: Identification of epidemiological risk factors in Barrett esophagus resulting in dysplasia and adenocarcinoma and its impact on prevention and early detection.
Aims: To evaluate epidemiological risk factors involved in the development of dysplasia and esophageal adenocarcinoma from Barrett esophagus in a specific population. To critically analyze the surveillance period, aiming to individualize follow-up time according to identified risks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!